Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

elbasvir / grazoprevir

Known as: ELBASVIR/GRAZOPREVIR, elbasvir and grazoprevir 
 
National Institutes of Health

Related topics

Related topics

2 relations
elbasvirgrazoprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir
Doravirine is a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus type 1 (HIV-1… Expand
  • table 1
  • figure 1
  • figure 2
2019
2019
Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
Treatment with all‐oral direct‐acting antiviral agents (DAAs) elbasvir/grazoprevir (EBR/GZR) is associated with high sustained… Expand
2019
2019
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
Background/Aims In the Republic of Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection. The… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
2019
2019
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse
Despite highly effective direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection, some patients… Expand
2019
2019
Direct acting anti‐viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease
Hepatitis C is a global health concern, with important implications in chronic kidney disease (CKD) due to its increased… Expand
Review
2018
Review
2018
Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.
Hepatitis C virus infection (HCV) is a common comorbidity in patients who have undergone kidney transplantation and is associated… Expand
2018
2018
Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China
Background and ObjectiveNew direct-acting antivirals (DAAs) have high efficacy and tolerability in the treatment of hepatitis C… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2017
Highly Cited
2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
BACKGROUND & AIMS Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
2017
2017
Cost‐effectiveness of elbasvir/grazoprevir use in treatment‐naive and treatment‐experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States
Among patients with chronic kidney disease (CKD) in the United States, HCV infection causes significant morbidity and mortality… Expand
2016
2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
BACKGROUND & AIMS Direct-acting antiviral agents have improved treatment outcomes for patients with hepatitis C virus (HCV… Expand
  • table 1
  • table 2
  • table 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE